novidades científicas Novo

16:13 European Cardiovascular Disease Statistics 2017
10:47 CETP inhibitor meets primary endpoint in CV outcome study
9:54 Arrhythmias and devices
14:31 Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial
14:18 Rivaroxaban or Aspirin for Extended Treatment of Venous Thromboembolism

ACS: implementation of new treatments lead to better outcomes in the real world

20 Setembro 2016

Cristoph Varenhorst
Uppsala Clinical Research Center
Dept. of Cardiology, Uppsala
University Hospital, Sweden

New options to manage high risk patients with dyslipidemia

20 Setembro 2016
0

New guidelines on heart failure

20 Setembro 2016
0

-->